Medtronic (MDT) Stock Overview
Develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
MDT Community Fair Values
Create NarrativeSee what 195 others think this stock is worth. Follow their fair value or set your own to get alerts.
Medtronic plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$96.86 |
| 52 Week High | US$106.33 |
| 52 Week Low | US$79.55 |
| Beta | 0.72 |
| 1 Month Change | -3.98% |
| 3 Month Change | -6.14% |
| 1 Year Change | 7.69% |
| 3 Year Change | 16.01% |
| 5 Year Change | -17.19% |
| Change since IPO | 66,467.24% |
Recent News & Updates
Recent updates
Medtronic: Navigating Tariffs And Chinese VBP Challenges
Feb 13Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Jan 05
Medtronic plc Just Recorded A 13% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 28Medtronic's (NYSE:MDT) Solid Earnings Are Supported By Other Strong Factors
Sep 03Medtronic's (NYSE:MDT) Returns On Capital Are Heading Higher
Jul 07
A Look At The Fair Value Of Medtronic plc (NYSE:MDT)
Jun 16Medtronic (NYSE:MDT) Will Pay A Larger Dividend Than Last Year At $0.71
May 30Medtronic: One Of The Best Times To Buy
Apr 21Is Now An Opportune Moment To Examine Medtronic plc (NYSE:MDT)?
Apr 14Medtronic: A Great Business, But With Low Growth
Mar 27Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Mar 20Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+
Strengths and Competitive Advantages:Diverse Product Portfolio: Medtronic operates across four key segments—Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes—providing revenue stability andMedtronic: Several Reasons For Optimism Before The Upcoming Earnings Release
Feb 15Medtronic: Undervalued But Underperforming - Why Innovation Isn't Enough To Lift The Stock
Feb 07Medtronic: A Dividend Aristocrat That's Poised To Pop
Jan 06Medtronic Stock Is Still A Great "Buy"
Dec 26Shareholder Returns
| MDT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.6% | 2.5% | 1.0% |
| 1Y | 7.7% | -8.9% | 14.6% |
Return vs Industry: MDT exceeded the US Medical Equipment industry which returned -8.9% over the past year.
Return vs Market: MDT underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| MDT volatility | |
|---|---|
| MDT Average Weekly Movement | 2.7% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDT's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 95,000 | Geoff Martha | www.medtronic.com |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
Medtronic plc Fundamentals Summary
| MDT fundamental statistics | |
|---|---|
| Market cap | US$124.18b |
| Earnings (TTM) | US$4.61b |
| Revenue (TTM) | US$35.48b |
Is MDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDT income statement (TTM) | |
|---|---|
| Revenue | US$35.48b |
| Cost of Revenue | US$12.36b |
| Gross Profit | US$23.13b |
| Other Expenses | US$18.51b |
| Earnings | US$4.61b |
Last Reported Earnings
Jan 23, 2026
Next Earnings Date
May 20, 2026
| Earnings per share (EPS) | 3.60 |
| Gross Margin | 65.17% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 59.6% |
How did MDT perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/22 10:18 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2026/01/23 |
| Annual Earnings | 2025/04/25 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medtronic plc is covered by 55 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kadambari Daptardar | Accountability Research Corporation |
| Harshit Gupta | Accountability Research Corporation |
| David Toung | Argus Research Company |